NCT03614728 · OUTCOME

Part 1: Overall Survival

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) · Source last updated 2023-02-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: Inter-Quartile Range
Time frame: Up to 30.8 months

What was measured

Overall survival is defined as time from first dose to death due to any cause.

Analysis population: All Treated Population.

Groups in this outcome

Part 1: GSK3326595 400 mg

Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.

Part 1: GSK3326595 300 mg

Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 1: GSK3326595 400 mg	13
Part 1: GSK3326595 300 mg	17

Reported measurements

Source class 1

Values in Months · Interval/dispersion: Inter-Quartile Range
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK3326595 400 mg	2.69	Not reported	2.14	12.98	Not reported
Part 1: GSK3326595 300 mg	2.96	Not reported	1.28	15.24	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
2.14
upper Limit
12.98
value
2.69
group Id
OG001
lower Limit
1.28
upper Limit
15.24
value
2.96

denoms

counts
group Id
OG000
value
13
group Id
OG001
value
17
units
Participants

description

Overall survival is defined as time from first dose to death due to any cause.

dispersion Type

Inter-Quartile Range

groups

description
Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.
id
OG000
title
Part 1: GSK3326595 400 mg
description
Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.
id
OG001
title
Part 1: GSK3326595 300 mg

param Type

MEDIAN

population Description

All Treated Population.

reporting Status

POSTED

time Frame

Up to 30.8 months

title

Part 1: Overall Survival

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice